Biofil Chemicals & Pharmaceuticals News

Biofil Chemicals Publishes Q3 FY25 Financial Results

Biofil Chemicals and Pharmaceuticals Limited has published its unaudited financial results for the quarter and nine months ended December 31, 2025 in newspapers as per SEBI regulations.

Biofil Chemicals and Pharmaceuticals Pays Rs 4.24 Lakh Fine to BSE Under Protest

Biofil Chemicals and Pharmaceuticals Limited paid a fine of Rs 4,24,823.60 to BSE Limited for alleged non-compliance with Regulation 17(1)(c) of listing regulations. The company had filed waiver applications with both NSE and BSE but received fines of Rs 95,000 and Rs 2,65,000 from BSE, stating there is no material impact on its financial or operational activities.

Biofil Chemicals and Pharmaceuticals Pays Rs 4.24 Lakh Fine to NSE Under Protest

Biofil Chemicals and Pharmaceuticals Limited paid a fine of Rs 4,24,823.60 to NSE after its waiver application for non-compliance under Regulation 17(1)(c) of listing regulations was rejected. The company states there is no material impact on its financial, operational or other activities from this regulatory action.

Biofil Chemicals Reports Mixed Quarterly Performance with Revenue Decline but Improved Profitability

Biofil Chemicals and Pharmaceuticals Limited reported revenue from operations of Rs 199.73 lakhs for the quarter ended September 30, 2025, down from Rs 334.02 lakhs in the previous year, while achieving a net profit of Rs 241.10 lakhs compared to a loss of Rs 55.78 lakhs in the same period last year. The company's board approved the unaudited financial results for the quarter and half-year ended September 30, 2025, showing improved profitability despite lower operational revenue across its pharma and chemicals divisions.